Brought to you by 
New investors Imperial Innovations, Astellas Venture join for Crescendo’s £17.5mm Series A; adds £2mm
17 Dec 2014
Executive Summary
Crescendo Biologics Ltd. (antibody fragment production using a proprietary transgenic mouse platform) raised £17.5mm ($28mm) in Series A financing, with a £6.5mm contribution from lead investor Imperial Innovations, which now has a 26.9% stake.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
-
Biotechnology
- Transgenics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
New investors Imperial Innovations, Astellas Venture join for Crescendo’s £17.5mm Series A; adds £2mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice